TY - JOUR T1 - Clinical Validation of Automated and Rapid mariPOC SARS-CoV-2 Antigen Test JF - medRxiv DO - 10.1101/2021.02.08.21250086 SP - 2021.02.08.21250086 AU - Juha M. Koskinen AU - Petri Antikainen AU - Kristina Hotakainen AU - Anu Haveri AU - Niina Ikonen AU - Carita Savolainen-Kopra AU - Kati Sundström AU - Janne O. Koskinen Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/05/2021.02.08.21250086.abstract N2 - Novel SARS coronavirus causing COVID-19 was recognized in late 2019. Diagnostics was quickly ramped up worldwide based on the detection of viral RNA. Based on the scientific knowledge for pre-existing coronaviruses, it was expected that the RNA of this novel coronavirus will be detected from symptomatic and at significant rates also from asymptomatic individuals due to persistence of non-infectious RNA. To increase the efficacy of diagnostics, surveillance, screening and pandemic control, rapid methods, such as antigen tests, are needed for decentralized testing and to assess infectiousness. The objective was to validate the analytical and clinical performance, and usability of a novel automated mariPOC SARS-CoV-2 test, which is based on the detection of structural viral proteins using sophisticated optical laser technology. Clinical performance of the test was evaluated against qRT-PCR with nasopharyngeal swab specimens collected from patients suspected of acute SARS-CoV-2 infection. Sensitivity of the mariPOC test was 100.0% (13/13) directly from swab specimens and 84.4% (38/45) from swab specimens in undefined transport mediums. Specificity of the test was 100.0% (201/201). The test’s limit of detection was 2.7 TCID50/test and had no cross-reactions with the tested respiratory microbes. Our study shows that the mariPOC can detect infectious individuals already in 20 minutes with clinical sensitivity close to qRT-PCR. The test targets conserved epitopes of SARS-CoV-2 nucleoprotein, making it robust against strain variations. The new test is a promising and versatile tool for syndromic testing of symptomatic cases and for high capacity infection control screening.Competing Interest StatementJMK, PA and JOK are employees at ArcDia International Ltd.Funding StatementArcDia International Ltd contributed the study with the mariPOC test system and consumables. The study was partly supported by Business Finland, the Finnish Funding Agency for Innovation, under the project reference 35239/31/2020.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was approved by the responsible Chief Medical Officer physician of Mehiläinen Oy, Dr., docent Kaisla Lahdensuo and by the responsible chief physician and area manager of SataDiag laboratory division, MD. Rutta Kuusela.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised line data is available upon request. ER -